Drug Trial Radar · NCT07284485
Immunoprevention for High-risk Lung Lesions
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
59
Planned (sponsor's estimate)
Start
May 21, 2026
Primary completion
Dec 15, 2027
Study completion Dec 17, 2029
Sponsor
- Lead sponsor
- Robert SamsteinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cantargia AB
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
Conditions
- High-risk Lung Nodules
Interventions
NadunolimabBiological
Nadunolimab will be administered 10mg/kg intravenously every 3 weeks for 4 doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rateTime frame: 3 months from initiation of study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.